Flyte Aviation, Inc.
VJET Healthcare Medical Devices
Flyte Aviation, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $819,000.00, up 95.0% from fiscal 2024. In the quarter to June 2026, revenue grew 380.7%, EPS grew 87.3%, free cash flow fell 26.7% and total debt rose 160.0%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
Follow VJET
Flyte Aviation, Inc. (VJET) Piotroski F-score
Flyte Aviation, Inc.'s Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | 1.00 |
| FY2024 | 2 | (2.00) |
| FY2023 | 4 | 1.00 |
| FY2022 | 3 | 2.00 |
| FY2021 | 1 | (1.00) |
| FY2020 | 2 | (1.00) |
| FY2019 | 3 | (1.00) |
| FY2018 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (78.77%) | (74.53%) | Fail | 0 |
| Positive operating cash flow | (8.30m) | (9.27m) | Fail | 0 |
| Rising return on assets | (78.77%) | (74.53%) | Fail | 0 |
| Cash flow above net income | 8.89m | 12.53m | Pass | 1 |
| Falling long-term leverage | 0.14 | 0.05 | Fail | 0 |
| Rising current ratio | 0.10 | 1.48 | Fail | 0 |
| No new shares issued | 1,080,600 | 171,800 | Fail | 0 |
| Rising gross margin | 92.31% | 90.00% | Pass | 1 |
| Rising asset turnover | 0.04 | 0.01 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| XAIR Beyond Air, Inc. compare | 5 |
| NXL Nexalin Technology, Inc. compare | 5 |
| DHAI DIH Holding US, Inc. compare | 4 |
| BIOLQ Biolase, Inc. compare | 3 |
| VJET Flyte Aviation, Inc. | 3 |
| AFIB Acutus Medical, Inc. compare | 3 |
| NUWE Nuwellis, Inc. compare | 3 |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | — |
| ADGM Adagio Medical Holdings, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover